Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Korrelation af tidlig FDG PET/CT og ctDNA i immun checkpoint inhibitor (ICI)-behandlede melanompatienter

11. november 2026 opdateret af: University of Wisconsin, Madison

Korrelation mellem tidligt interval 18F-fluordeoxyglucose positronemissionstomografi/computertomografi (PET/CT) og cirkulerende tumor-DNA (ctDNA) hos patienter med avanceret melanom behandlet med immune checkpoint-hæmmere

The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.

Primary Objective

• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.

Secondary Objectives

  • To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

25

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • University of Wisconsin Hospitals and Clinics (UWHC)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.

Beskrivelse

Inclusion Criteria:

  • Willing to provide informed consent.
  • Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
  • Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
  • Individuals at least 18 years of age.
  • Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
  • Willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

  • Not able to receive treatment with ICI therapy
  • Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
  • Women who are pregnant, lactating, or planning on becoming pregnant during the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Avancerede melanompatienter med immun checkpoint-hæmmere

research scan 3-4 weeks after start of immunotherapy

Andre navne:
  • 18F-FDG PET/CT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Tidsramme: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

ctDNA level is monitored per standard of care in this population, data from chart review.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Tidsramme: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Tidsramme: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Tidsramme: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve).

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR).

up to 12 months after the first ICI dose (approximately 1 year on study)
Disease Control Rate (DCR)
Tidsramme: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR.

up to 12 months after the first ICI dose (approximately 1 year on study)
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Tidsramme: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0

up to 12 months after the first ICI dose (approximately 1 year on study)
Progression Free Survival (PFS)
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Overall Survival (OS)
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Tidsramme: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Vincent Ma, MD, University of Wisconsin, Madison

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. januar 2024

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2029

Datoer for studieregistrering

Først indsendt

27. december 2023

Først indsendt, der opfyldte QC-kriterier

27. december 2023

Først opslået (Faktiske)

10. januar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2023-1089
  • A534260 (Anden identifikator: UW Madison)
  • UW23077 (Anden identifikator: UWCCC)
  • Protocol Version 2/12/2024 (Anden identifikator: UW Madison)
  • NCI-2023-11059 (Registry Identifier: NCI Trial ID)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .